Curr Opin Lipidol. 2018 Apr;29(2):125-132. doi: 10.1097/MOL.0000000000000483.
DNA copy number variations (CNVs) are quantitative structural rearrangements that include deletions, duplications, and higher order amplifications. Because of technical limitations, the contribution of this common form of genetic variation to regulation of lipid metabolism and dyslipidemia has been underestimated.
Recent literature involving CNVs and dyslipidemias has focused mainly on rare CNVs causing familial hypercholesterolemia, and a common CNV polymorphism as the major determinant of lipoprotein(a) plasma concentrations. Additionally, there is tantalizing evidence of largely uninvestigated but plausible presence of CNVs underlying other dyslipidemias. We also discuss the future role of improved technologies in facilitating more economic, routine CNV assessment in dyslipidemias.
CNVs account for large proportion of human genetic variation and are already known to contribute to susceptibility of dyslipidemias, particularly in about 10% of familial hypercholesterolemia patients. Increasing availability of clinical next-generation sequencing and bioinformatics presents a cost-effective opportunity for novel CNV discoveries in dyslipidemias.
DNA 拷贝数变异(CNVs)是一种定量结构重排,包括缺失、重复和更高阶的扩增。由于技术限制,这种常见的遗传变异形式对脂质代谢和血脂异常的调节作用一直被低估。
涉及 CNVs 和血脂异常的最新文献主要集中在导致家族性高胆固醇血症的罕见 CNVs 和作为脂蛋白(a)血浆浓度主要决定因素的常见 CNV 多态性上。此外,还有一些引人入胜的证据表明,在其他血脂异常中,存在着大量尚未被充分研究但似乎存在的 CNVs。我们还讨论了改进技术在促进血脂异常中更经济、常规的 CNV 评估方面的未来作用。
CNVs 占人类遗传变异的很大比例,已知其与血脂异常的易感性有关,特别是在约 10%的家族性高胆固醇血症患者中。临床下一代测序和生物信息学的日益普及为血脂异常中的新型 CNV 发现提供了一种具有成本效益的机会。